The chromosomal translocation t(12;16)(q13;p11) is a common genetic alteration in myxoid and round-cell liposarcomas. It results in transcription of various chimeric FUS/CHOP fusion transcripts that encode different oncogenic proteins. Recent reports suggest that these may have different neoplastic transformation activities. To audit this hypothesis, we transfected expression plasmids for the two major variant FUS/ CHOP transcripts I and II in NIH 3T3 cells and determined the number of outgrowing foci as well as their growth potential in soft agar. In addition, we compared tumour growth in nude mice upon subcutaneous injection of the respective transfectants. No significant differences in transformation assays in vitro and in vivo were observed, suggesting that both variant transcripts confer comparable transforming activities. The histopathological picture of tumours derived from both cell populations resembles high-grade spindle cell sarcomas. This suggests that both FUS/CHOP variants cause similar patterns of differential gene expression. This hypothesis was confirmed by mRNA-expression profiles of the respective cell clones. Strong overexpression of the pentaxin-related gene (PTX), the osteoblast-specific factor 2 (osf-2), the basic Kruppel-like factor (bklf), the leucoprotease inhibitor, and the cyclophilin B were observed in both types of FUS/ CHOP-transfected cell clones. Taken together, our data suggest that different FUS/CHOP variants cause transformation of mesenchymal cells via the same pathways with comparable efficacy.
Introduction
Soft tissue liposarcomas frequently display stable chromosomal translocations that result in transcription and translation of chimeric transcription factors (Rabbitts, 1994) . Among histological defined subtypes, most myxoid and round-cell liposarcomas demonstrate a t(12;16)(q13;p11) chromosomal translocation. This results in the expression of a fusion gene encoding the N-terminus of the FUS (fused in liposarcoma [syn. TLS]) gene, fused in frame to the coding region of the CHOP gene (C/EBP homologous protein) (Aman et al., 1992; Crozat et al., 1993; Rabbitts et al., 1993) . As both the wild-type CHOP protein and the FUS/CHOP fusion protein form dimers with members of the C/EBP transcription factor family, the expression of the FUS/ CHOP fusion protein is thought to result in the deregulated transcription of genes involved in the control of differentiation and growth of pre-adipocytes harbouring the respective chromosomal translocation (Crozat et al., 1993; Zinszner et al., 1994) . Thus, the important role of the normal CHOP protein in controlling adipocyte differentiation and growth arrest (Barone et al., 1994; Butterwith, 1994) may be significantly hampered by the expression of the chimeric FUS/CHOP gene. Furthermore, the chromosomal translocation results in the FUS promoter-mediated constitutive expression of the CHOP gene, whereas in normal cells transcription of the CHOP gene is tightly regulated and generally strongly repressed (Carlson et al., 1993; Wang et al., 1998) . Recently, the induction of liposarcomas by the constitutive overexpression of the FUS/CHOP fusion transcript in transgenic mice further underlined the crucial role of FUS/CHOP overexpression in the pathogenesis of liposarcomas (Perez-Losada et al., 2000) .
Most of the FUS/CHOP-carrying myxoid liposarcomas harbour FUS/CHOP fusion transcripts type I or II, generated by alternate splicing of exon 5 or 7 of the FUS gene to exon 2 of the CHOP gene (Aman et al., 1992; Crozat et al., 1993; Panagopoulos et al., 1995 Panagopoulos et al., , 1997 Willeke et al., 1998; Kanoe et al., 1999; Kuroda et al., 1999; Schneider-Stock et al., 1999) . In previous studies, the oncogenic activity of these two individual FUS/ CHOP fusion transcripts has been evaluated with conflicting results in different experimental settings. Type I fusion transcript was found to transform NIH 3T3 cells (Zinszner et al., 1994) , while in an analysis of another group failed to transform 3T3-L1 cells (Batchvarova et al., 1995) . The type II FUS/CHOP transcript was analysed in yet another setting utilizing ST-13, a murine preadipocytic cell line, and demonstrated transforming activity and tumour formation in nude mice (Kuroda et al., 1995) (Figure 1) .
The exact role of the FUS/CHOP fusion gene in the pathogenesis of liposarcomas is still unclear. It has been postulated that FUS/CHOP acts as an abnormal transcription factor that deregulates the transcriptional control of a number of target genes and causes relaxation of functions critical for growth and differentiation control (Thelin-Jarnum et al., 1999) . It is still unclear whether the different types of FUS/CHOP fusion proteins recruit identical or different sets of target genes. To address this question, we defined gene expression profiles and compared cells stably transfected either with FUS/CHOP type I or II transcript, or with an empty control vector. Several differentially expressed genes were identified and a striking similarity was documented for either FUS/CHOP type I or II transcript-expressing NIH 3T3 cells.
Results

Similar transforming capacities of FUS/CHOP transcripts type I and II -foci formation on monolayer cultures and colony formation in soft agar
Abrogation of normal contact inhibition and acquisition of anchorage-independent growth properties are characteristic features of transformed cells. To test and compare the transforming potential of each variant, FUS/CHOP fusion transcript focus-forming and softagar assays were carried out following transient transfection of NIH 3T3 cells. Fusion protein expression in transfected cells was confirmed by Western blot analysis (Figure 2 ). Foci formation of NIH 3T3 cells was assayed 4 weeks after transfecting 1 Â 10 3 cells with 5 mg of the respective mammalian expression vector encoding one of the variant FUS/CHOP fusion transcripts I and II (Figure 3) . NIH 3T3 cells either nontransfected (non), transfected without adding plasmid DNA (mock), or transfected with the empty mammalian expression vector (vector) served as controls for spontaneous background foci formation. Comparable transfection efficiencies were confirmed by control transfection experiments using vector pEGFP-C1 (Clontech) coding for enhanced green fluorescent protein and FACS-based fluorescence measurement 24 h after transfection. All experiments were performed in triplicate and using NIH 3T3 cells of the same low passage number. Comparable transformation capacities of type I and II FUS/CHOP fusion transcripts on NIH 3T3 fibroblasts were observed. The numbers of foci observed in FUS/CHOPtransfected NIH 3T3 cells exceeded those of the control cells fourfold. The results shown in Figure 3a are the median of three independent transfection experiments.
Soft agar assays were carried out to test whether expression of the variant FUS/CHOP fusion transcripts confers the ability to grow in an anchorage-independent manner to normal fibroblasts. As shown in Figure 3b , both fusion transcripts yielded high numbers (80-120) of colonies in soft agar, whereas NIH 3T3 cells transfected with empty vector or mock-transfected cells did not.
Tumorigenicity in nude mice
To determine whether the apparent transforming properties of both fusion transcripts confer a fully malignant phenotype in vivo, stably transfected cells were inoculated subcutaneously into nude mice. Within 2 weeks, comparable strong tumour development was observed for both of the respective NIH 3T3 cell clones analysed and previously transfected with type I or II FUS/CHOP fusion transcript expression vector (data not shown). Western blot analysis of the harvested The FUS/CHOP oncoprotein is believed to exert its oncogenic properties through transcriptional activation of critical target genes involved in the regulation of cell growth and differentiation. The molecular identity of most of these FUS/CHOP target genes is not yet known. To compare the transactivating potential of variant FUS/CHOP fusion proteins and to identify novel candidate target genes, we established comprehensive gene expression profiles of cells stably transfected with either FUS/CHOP type I or II transcript. Using the Affymetrix U74A Mouse Genome Array, which allows for the simultaneous analysis of more than 12 000 sequences, we found overlapping sets of genes significantly activated (43-fold change) by either FUS/CHOP fusion transcript (Table 1) . Each of the top 10 scoring genes found to be activated by transcript I was also found among the top scoring genes activated by transcript II, although not at the identical position (between ranks 1 and 13). Vice versa, those 10 genes upregulated the strongest in transcript II-transfected cells were found between ranks 1 and 22 of transcript Itransfected cells. The genes that were induced by both transcripts at highest levels included connective tissue growth factor-related protein (WISP-2), secretory leukoprotease inhibitor gene, pentaxin-related gene (PTX), and osteoblast specific factor (Osf)-2. We verified the micro-array data by Northern blot analysis for a limited number of genes and found similar activation of the genes encoding PTX, secretory leukoprotease inhibitor (Slpi), Osf-2, cytochrome P450 (Cyp-) 1-b-1, and basic Kruppel-like factor (BKLF), in both transcript I-and transcript II-transfected NIH 3T3 cells ( Figure 5 ).
Discussion
FUS/CHOP fusion transcripts, as a result of the stable translocation (12;16)(q13;p11), represent an ideal model to evaluate tumorigenesis in soft tissue liposarcomas. The mere demonstration of these unique sequences raises immediate questions regarding how the resulting protein influences the differentiation of the tumor.
Our results confirm that FUS/CHOP fusion transcripts are able to confer transforming activity to NIH 3T3 fibroblasts. Furthermore, no major difference could be observed in the respective transforming capacities of type I and II FUS/CHOP transcripts, as analysed by measuring the capabilities for foci formation, anchorage-independent growth, and tumour formation in nude mice. These findings indicate that FUS/CHOP transcripts type I and II inherit the capacity to transform NIH 3T3 mouse fibroblasts. In former reports, the respective fusion transcripts were evaluated in different experimental settings. Utilizing pre-adipocyte cell lines (ST-13, 3T3-L1), a difference in the transforming capacity among the fusion transcripts has been discussed (Zinszner et al., 1994; Kuroda et al., 1997) . Our observation of comparable transforming activities of the variant fusion transcripts within identical experimental settings suggests that the differences reported to date are dependent on cell type rather than on these two types of fusion transcripts. Furthermore, the comparable capacity to induce transformation of NIH 3T3 fibroblasts suggests that exons 6 and 7, which are retained in transcript I only, are not essential for the transforming process. It has already been shown that constitutive overexpression of the CHOP gene alone does not exert the same transforming activity in NIH 3T3 cells as compared to those induced by the FUS/ CHOP fusion transcripts (Zinszner et al., 1994) . Our data further corroborate the importance of the aminoterminal FUS component as a transcriptional activation domain in the transformation process. Functional analysis of the FUS gene by other groups has yielded similar results. They demonstrated a 20-fold increase in dependent genes by the N-terminal domain, while the C-terminal domain of FUS had no impact on expression in these experiments (Powers et al., 1998) . One group working on transgenic mice was able to generate animals with various altered FUS/CHOP proteins expressed by murine mesenchymal stem cells. Interestingly, they demonstrated that the FUS domain was crucial for the phenotype development of liposarcomas. Alternative promoters initializing CHOP were unable to induce liposarcomas comparable to those observed in FUS/CHOP transgenic mice (Perez-Losada et al., 2000) .
Other groups have discussed that distinct fusion transcripts, such as transcript II, could be associated with a certain histological subtype (round-cell liposarcoma) and a less favourable prognosis (Kuroda et al., 1997) . In contrast, our data suggest that there is no obvious difference in functional analysis of FUS/CHOP fusion transcript subtypes in the selected experimental setting. Furthermore, no prognostic impact of tumours with FUS/CHOP fusion transcripts as compared to FUS/CHOP negative tumours has yet been defined (Antonescu et al., 2001 ).
Given a defined experimental setting, gene expression experiments should be able to describe genes influenced by the FUS/CHOP gene. Using Affymetrix s highdensity arrays, we observed the gene expression profiles of FUS/CHOP fusion transcript I-and II-expressing cell lines to be strikingly similar. Overexpression, as analysed in Chip hybridization experiments, was verified by Northern blot experiments in selected cases, which demonstrated comparable results between transcript Iand transcript II-transfected cells. Although these experiments were not able to distinguish between direct and indirect target genes of FUS/CHOP-mediated transcriptional activation, both classes of genes may contribute to the malignant phenotype of FUS/CHOPexpressing cells.
PTX was originally cloned as an interleukin-I inducible gene from human umbilical vein endothelial cells (Breviario et al., 1992) . This group of proteins, which include c-reactive protein, has been characterized as acute-phase proteins involved in the inflammatory response to various stimuli. PTX is able to bind C1q, which presents the first step in complement activation. Besides its presence in endothelial cells, PTX was observed in hepatocytes, fibroblasts, and monocytes after inflammatory stimulation. The relevance of the PTX expression for liposarcomas harbouring FUS/ CHOP fusion transcripts is still unclear. Pentaxins have not yet been reported in association with liposarcoma tumorigenesis.
Osf-2 has been originally found as an osteoblastspecific transcription factor. Cumulative evidence indicates, however, that osteoblasts and adipocytes share a common mesenchymal stem cell precursor. In accordance with this hypothesis, bone morphogenic Gene accession numbers are given in the far left column. In the first data column, fold change values are provided. In data columns 2 and 3, the average difference values of FC-transfected and vector-alone-transfected cells are compared. Genes identified in both pEXL-FC I-and pEXL-FC II-transfected cell lines are given in bold rat developing kidney (Ito et al., 2002) and is overexpressed in embryonal rhabdomyosarcomas (Genini et al., 1996) . Bklf is a widely expressed member of the Kruppel-like family of transcription factors. Although the exact physiological role of Bklf is not known, many other Kruppel-like transcription factors have been implicated in growth regulation and cancer (Black et al., 2001) .
CypB has been found to be a tumor-specific antigen in lung cancer, which can be recognized by specific cytotoxic T cells in an HLA-restricted manner (Gomi et al., 1999) , and antigen-specific immunotherapy targeting CypB in lung cancer has already been included in clinical trials (Gohara et al., 2002) .
Slpi belongs to a family of tissue inhibitors of specific proteinases. Although they have not been associated with human cancer, these tissue inhibitors may show involvement similar to that of the metalloproteinases (TIMPs), a more studied group of tissue inhibitors. TIMPs, for example, demonstrate both inhibitory and stimulatory effects on tumorigenesis in many animal models (Jiang et al., 2002) .
How does the detected differential expression illustrated here compare to data already reported in the literature? Utilizing a PCR-based subtractive hybridization technique, differential expression of glia-derived nexin gene (PN-1) was reported, a serine protease inhibitor possibly comparable in its role to SLPI (Thelin-Jarnum et al., 1999). Another gene detected was neuronatin, involved in brain development. Detection of this gene seemed to indicate that the tumour originated neurally. An overexpression of RET has also been reported, a gene which leads to variant tumour formations in cases of germline mutations (Eng, 1996) . Finally, one group defined an epistatic relationship between FUS/CHOP and DOL54/MSF (megakaryocyte stimulatory factor), a gene discovered by representational difference analysis (Kuroda et al., 1999) . However, the specificity of this relationship mandates further analysis, since another sarcoma subtype, malignant fibrous histiocytoma, demonstrated DOL54 expression nearly as often as myxoid and round-cell liposarcomas (Domoto et al., 2003) .
Summarizing these data, technically different modes of gene expression profiling have defined novel and promising candidate target genes for FUS/CHOPmediated oncogenesis. Further studies will clarify which candidates are essential for the oncogenesis of soft tissue liposarcoma.
Materials and methods
RT-PCR for FL FUS/CHOP fusion transcripts type I and II
Total RNA was extracted from shock-frozen tumour samples, known to express the FUS/CHOP transcript, using TRI reagent (Molecular Research Center, Inc., Cincinatti, OH, USA). To eliminate contamination of DNA within the RNA preparations, samples were digested with RNase-free DNase I, as recommended by the supplier (Life Technologies, Inc.; 15 min at 251C). Template cDNA was synthesized from 0.5 mg of total RNA using Superscript reverse transcriptase (Life Technologies Inc.). One-tenth of the cDNA was used as the template for PCR amplification. Diagnostic nested RT-PCR was performed as previously reported (Willeke et al., 1998) . To obtain the entire coding sequence of the FUS/CHOP fusion gene, a FL nested PCR was established. 
Sequence analysis of RT-PCR products
Amplified sequences were cloned into the plasmid vector pCR2.1. (InVitrogen, San Diego, CA, USA). Plasmid DNA was prepared with the Qiagen Plasmid Extraction Kit (Qiagen, Hilden, Germany), followed by sequencing with the Cy5 0 AutoAutoRead sequencing Kit (Pharmacia Biotech). Sequencing reactions were analysed on a polyacrylamide/urea gel using an ALFExpress DNA sequencer (Pharmacia Biotech). The PCR products containing the variant sequences of the generated FUS/CHOP fusion transcripts were cut out of the pCR2.1 plasmid and subcloned into pUC 18.
Western blot
Proteins from transfected and control cell lines and tumour tissue were solubilized in Laemmli buffer. The proteins were Figure 5 Northern blot analysis. In all, 7 mg of total RNA isolated from untransfected NIH 3T3 cells (NIH 3T3), from NIH 3T3 cells stably transfected with empty vector (pEXL), or from NIH 3T3 cells stably transfected with cDNA expression vectors encoding FUS/CHOP fusion transcript type I (pEXL-FC I) and type II (pEXL-FC II) was fractionated on an 1.4% agarose gel and analysed by Northern blot hybridization using different RT-PCRderived fragments as probe. Expression of the following genes was tested: bklf ¼ CACCC-box-binding factor bklf (Acc. No. U36340), cypB ¼ cytochrome P450 subunit (X78445), leukoprotease inhibitor ¼ secretory leukoproteinase inhibitor gene (AF002719), osf-2 ¼ osteoblast-specific factor 2 (D13664), pentaxin ¼ pentaxinrelated gene (X83601), gapdh ¼ glyceraldehyde phosphate dehydrogenase (internal control) then electrophoresed in 10% SDS gels and blotted onto PVDF membranes (Biorad, Mu¨nchen, Germany). Filters were probed for the antibody GADD 153 sc-793 (Santa Cruz Biotech., Santa Cruz, USA), detecting wild-type CHOP (30 kDa), FUS/ CHOP type I (75 kDa), and FUS/CHOP type II (66 kDa), and the resulting bands were visualized with chemiluminescence (Perkin-Elmer, Boston, USA) (Figure 2) .
Expression of the variant FUS/CHOP fusion transcripts in a mammalian expression vector
The FL sequences were released from the pUC 18 plasmid by digestion with EcoRI and HindIII, blunted by the Klenow fragment and ligated into a derivative of the CMV promoter containing pUHD10 mammalian expression vector, differing from this vector only in the multiple cloning site (pEXL, R Ridder, unpublished, Heidelberg, Germany). DNA sequencing was performed to confirm the 5 0 -3 0 ligation.
Transfection of NIH 3T3 embryonal mouse fibroblasts
Cells were cultured in 175 cc 2 bottles and maintained in RPMI-1640 medium with glutamyl, supplemented with 10% foetal calf serum, 10 000 units/cc penicillin, and 1000 mg/ml streptomycin (Invitrogen, Karlsruhe, Germany) at 371C in a humidified incubator with a 5% CO 2 atmosphere. The following day, cells were transfected using 5 mg of plasmid DNA (FUS/CHOP type I/II integrated in the expression vector) according to the Effectene transfection protocol (Qiagen, Hilden, Germany). Transient transfectants were used for in vitro assays, while stable transfectants after cotransfection with SPV 2Neo (one-tenth) and selection with 450 mg/ml G418 (Life Technologies) for 2 weeks were used for the animal experiments. To evaluate the transfection efficiency, the pEGFp plasmid, encoding enhanced green fluorescent protein, was co-transfected (1/10 th of FUS/CHOP expression vector DNA) and analysed 24 h after transfection using a FACS reader. Transfectants were confirmed to harbour the FUS/CHOP fusion transcript by a control RT-PCR. To analyse the transforming activities of the structurally different FUS/CHOP transcripts of type I and II, the coding regions were individually cloned into mammalian expression vectors. This resulted in the generation of plasmids pEXL-FC I and pEXL-FC II, and allowed the constitutive overexpression of the respective fusion transcript under the control of the CMV promoter (Figure 1) . A Western blot analysis of transfected cells and control cells confirmed the expression of fusion protein in the cell clones transfected with either FUS/CHOP transcript I (fusion protein 75 kDa) or FUS/CHOP transcript II (fusion protein 66 kDa).
Foci formation
Foci formation was studied 4 weeks after plating 1 Â 10 3 FUS/ CHOP fusion transcript type I/II-transfected NIH 3T3 cells on 9.5-cm cell culture dishes. Controls constituted of transfection lacking the expression plasmid, the empty vector, and nontransfected cells.
Anchorage-independent growth
A soft agar assay was used to study anchorage-independent growth. 5 Â 10 4 cells from each FUS/CHOP type I/II transfected cell and controls were suspended in 0.36 w/v% low-gelling bactoagar in a 1 : 1 mixture of Dulbecco's minimal essential culture medium (Sigma) containing 10% calf serum, 1% glutamine, and 1% penicillin/streptomycin. This suspension was plated over a cushion of 0.72 w/v% low-gelling bactoagar in the same medium. Colonies (450 mm) were counted under an inverted microscope 8 weeks after plating.
Tumorigenicity in nude mice
Tumorigenicity of stable transformants in vivo was examined using athymic nude mice. 5 Â 10 5 cells were injected subcutaneously to the hind foot of 6-week-old female Swiss nude mice. Tumour formation was continuously monitored and the animals were killed after 18 days. Tissue samples were fixed in 10% formaldehyde. For histopathological examination, formalin-fixed, paraffin-embedded tissue sections were stained with haematoxylin and eosin (H&E) and macroscopically studied. FUS/CHOP expression in the resected tumours was demonstrated by a control Western blot, demonstrating the respective fusion proteins within the tumour tissue.
Gene expression analysis in stable transfectants
Cells were plated at a density of 1.2 Â 10 5 into a six-well culture plate and were maintained in RPMI-1640 medium with glutamyl, supplemented with 10% foetal calf serum, 10 000 U/cm 3 penicillin, 1000 mg/ml streptomycin, and G-418 (conc. in medium: 400 mg/ml) at 371C in a humidified incubator with a 5% CO 2 atmosphere. After the cells reached an 80-90% confluence, they were harvested, washed, and snap-frozen for storage at À801C.
Preparation of target cRNA
For each sample, total RNA (Rneasy s , Qiagen) was extracted and pooled from cell pellets taken from three independent experiments performed with the same treatment procedure. Sample preparation was performed according to the Affymetrix Gene Chip Expression Analysis Technical Manual (version 1999, Affymetrix Santa Clara, CA, USA), with minor modifications. In brief, ds-cDNA was synthesized from 12 mg of total RNA by using the Superscript Choice System (Invitrogen, Karlsruhe, Germany) and T7-oligo-dT(24)-primer (Genset, Paris, France). ds-cDNA was then purified using the High Pure PCR Purification Kit (Roche Diagnostics, Mannheim, Germany) and eluted in 40 ml DEPC-treated ddH 2 O.
Biotinylated cRNA was synthesized using the Bioarray High Yield RNA Transcription Labelling Kit (Enzo Diagnostics, Farmingdale, NY, USA), incubation was for 4 h at 371C. The labelled cRNA was then purified using the RNeasy total RNA Isolation Kit and fragmented for 35 min at 941C in a buffer containing 100 mM potassium acetate, 40 mM Tris-acetate, 20 mM magnesium acetate, and 2 mM dithiothreitol (pH 7.9).
Hybridization to affymetrix oligonucleotide microarrays
In total, 12 mg fragmented cRNA was added to 300 ml hybridization solution containing 50 pM control Oligonucleotide B2 (Affymetrix, Santa Clara, CA, USA), 0.1 mg/ml herring sperm DNA, and 0.5 mg/ml acetylated BSA in 1 Â MES hybridization buffer (100 mM MES, 1 M [Na þ ], 20 mM EDTA, 0.01% Tween 20). The cocktail was hybridized to the Murine Genome U74A Array from Affymetrix. Hybridization was carried out for 16 h at 451C in a GeneShip Hybridization Oven 640 (Affymetrix Santa Clara, CA, USA) at 60 r.p.m.
Washing, staining, detection, data analysis
The microarrays were washed and stained in an Affymetrix Fluidic station 400 following a three-step protocol. First, staining was achieved by using a phycoerythrin-streptavidine conjugate (Molecular Probes, Eugene, OR, USA). Second, amplification was carried out by incubation with a biotinylated anti-streptavidine antibody (Vector Laboratories, Burlinggame, CA, USA), followed by a second round of staining with the phycoerythrin-streptavidine conjugate again. Hybridization signals were detected using a Hewlett-Packard GeneArray Scanner (Bo¨blingen, Germany) and the resulting images were analysed with Affymetrix Analysis Software (version mas4).
Northern blot analysis
Northern gels loaded with 7 mg of RNA were electrophoresed, and RNA was transferred to Hybond N þ nylon membranes (Amersham Pharmacia Biotech, Freiburg, Germany). Probes were generated by RT-PCR using the following primers:
Bklf (GenBank Acc. No. U36340): bklf-fwd1 (5 0 -TCCTGGCGTGCAGCCCTTTGG-3 0 ) and bklf-rev1 (5 0 -TCTTCTGTGTGCTTTCAAGTG-3 0 ) Leukoprotease inhibitor gene (AF002719): leuki-fwd1 (5 0 -CCTGTTCCCATTCGCAAACCAG -3 0 ), leuki-rev1 (5 0 -GCGCCAATGTCAGGGATCAGG -3 0 ). Cyp1-b1 (X78445): cypB-fwd1 (5 0 -CCAACCTG-CCATATGTCATGG -3 0 ) cypB-rev1 (5 0 -ACA TGGATTCTAACCGACTTGG -3 0 ).
Osf-2 (D13664): osf2-fwd1 (5 0 -CCACGAGGTGTCCTAGAAAGG -3 0 ) and osf2-rev1 (5 0 -CCA TTGTAGAGGTCGCTAAGG -3 0 ) Pentaxin-related gene (X83601): pentaxin-fwd1 (5 0 -TCTTTTAGTACTTGCATTTGG -3 0 ) and pentaxin-rev1 (5 0 -AACCCGATCCCAGATATTGAAG -3 0 ) Glyceraldehyde 3-phosphate-dehydrogenase (GAPDH): gapdh-fwd 1 (5 0 -CAAGTTCAACGGCACAGTCAAGG-3 0 ) and gapdh-rev1 (5 0 -ATTGGGGGTAGGAACACGGA AGG-3 0 ). Labelling was performed using PCR (Taq Polymerase Kit; Invitrogen) and 50 ng of gel-purified PCR fragment as template. The filters were washed with a final stringency of 0.1 Â SSC, 0.5% SDS at 601C for 30 min, and exposed using intensifying screens at À701C (rehybridization of filters with a probe specific for the housekeeping gene GAPDH was performed after washing the filters with 0.1% SDS, 20 mM Tris-HCl, pH 7.0 for 60 min at 801C).
